USANA Health Sciences, Inc. (USNA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
USNA Revenue Growth
Revenue Breakdown (FY 2025)
USNA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
USNA Revenue Analysis (2014–2025)
As of May 8, 2026, USANA Health Sciences, Inc. (USNA) generated trailing twelve-month (TTM) revenue of $925.3 million, reflecting solid growth of +5.9% year-over-year. The most recent quarter (Q4 2025) recorded $226.2 million in revenue, up 5.9% sequentially.
Looking at the longer-term picture, USNA's 5-year compound annual growth rate (CAGR) stands at -4.0%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $1.19 billion in 2018.
Revenue diversification analysis shows USNA's business is primarily driven by All Other (100%). With over half of revenue concentrated in All Other, the company maintains significant focus in this area while developing other growth vectors.
When compared to Consumer Defensive sector peers including NUS (-14.3% YoY), NATR (+7.3% YoY), and NHTC (-10.5% YoY), USNA has underperformed the peer group in terms of revenue growth. Compare USNA vs NUS →
USNA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| USNACurrent | $925M | +5.9% | -4.0% | 5.5% | |
 NUS | $1.5B | -14.3% | -10.5% | 6.1% | |
 NATR | $480M | +7.3% | +4.5% | 5.2% | |
 NHTC | $40M | -10.5% | -8.5% | -4.5% | |
 HLF | $5.0B | +3.7% | -1.9% | 8.8% | |
 PLBY | $121M | -19.0% | -3.9% | -2.7% |
USNA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $925.3M | +8.3% | $724.4M | 78.3% | $50.9M | 5.5% |
| 2024 | $854.5M | -7.2% | $678.8M | 79.4% | $66.3M | 7.8% |
| 2023 | $921.0M | -7.8% | $731.6M | 79.4% | $93.1M | 10.1% |
| 2022 | $998.6M | -15.8% | $791.3M | 79.2% | $107.6M | 10.8% |
| 2021 | $1.19B | +4.6% | $955.5M | 80.5% | $170.2M | 14.3% |
| 2020 | $1.13B | +7.0% | $911.8M | 80.4% | $176.5M | 15.6% |
| 2019 | $1.06B | -10.8% | $858.9M | 81.0% | $146.2M | 13.8% |
| 2018 | $1.19B | +13.6% | $971.8M | 81.7% | $188.4M | 15.8% |
| 2017 | $1.05B | +4.1% | $851.9M | 81.3% | $132.5M | 12.7% |
| 2016 | $1.01B | +9.5% | $812.4M | 80.7% | $138.6M | 13.8% |
See USNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs USNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare USNA vs WMT
Side-by-side business, growth, and profitability comparison vs Walmart Inc..
Start ComparisonUSNA — Frequently Asked Questions
Quick answers to the most common questions about buying USNA stock.
Is USNA's revenue growth accelerating or slowing?
USNA maintains +5.9% revenue growth, in line with its 5-year CAGR of -4.0%. TTM revenue stands at $925M. Growth rate remains consistent with historical average.
What is USNA's long-term revenue growth rate?
USANA Health Sciences, Inc.'s 5-year revenue CAGR of -4.0% reflects the sustained expansion pattern. Current YoY growth of +5.9% is near this long-term average.
How is USNA's revenue distributed by segment?
USNA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.